STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL DRUGS: TOWARDS AN IMPLEMENTATION OF THE TREATMENT PATHWAY IN ONCO-HEMATOLOGY

Ravenna Sala Corelli
26 - 27 May 2017
26th May

1st Session: to transplant or not to Transplant: This is the question
1st part 13.30 - 16.10
1) Hematopoietic Stem cell transplantation (HSCT) in the era of novel drugs: The EBMT perspective
   Duarte R, Spain
2) HSCT in acute myeloid leukemia
   Nagler A, Istrael
3) HSCT in Philadelphia-+ ALL
   Rambaldi A, Italy
4) Cellular therapy activity in Europe
   Bonini C, Italy
5) Novel antibodies for Ph-neg ALL: can we use them as a bridge to transplant
   Martinelli G, Italy
6) Infection Control Strategy In High Risk HSCT
   Aversa F, Italy
7) Treatment strategies for fungal infections
   Luppi M, Italy
16.10 - 16.30 Coffee break

2nd part 16.30 - 19.00
1) Cell therapy for solid tumors
   Bonifazi F, Pedrazzoli P, Tosi P
2) HSCT for refractory-relapsed Germ cell tumor
   Comoli P, Italy
3) HSCT in Breast cancer
   Necchi A, Italy
4) Debate: Mobilization of HSCT in multiple myeloma: is chemotherapy still needed
   Duarte R, Spain
   Yes
   Lanza F, Italy
5) Endothelial complications post SCT: how can we predict and prevent it?
   How can we treat it?
   Olivieri A, Italy
6) Quality management and accreditation in transplantation: is it worth doing!
   McGrath E, UK
7) Nurses impact on HSCT outcome
   Babic A, Italy
27th May

1st Session: Novel drugs: too many or still not enough!
Is transplantation still the thing to do?
1st part 8.30 - 10.40
1) Novel drugs in low grade nHL: are them better than SCT
   Zaja F, Italy
2) How I treat aggressive CLL
   Cuneo A, Italy
3) Which is the role of Immune check point inhibitors in malignant lymphomas
   Carlostella C, Italy
4) Role of monoclonal antibodies for the management of Hodgkin’s lymphoma
   patients who are candidate to HSCT
   Martino M, Italy
5) Immune check point inhibitors in solid tumors with special emphasis on lung cancer:
   can we use it in combination with cellular therapy?
   Bennati C, Italy
6) Multiple myeloma in young patients: one-two or no transplants, what is better?
   Cavo M, Italy

10.40 - 11.00 Coffee break

2nd part 11.00 - 13.30
1) Novel Monoclonal antibodies in MM
   Bacigalupo A, Lucchesi A
   Malavasi M, Italy
2) Rethinking the treatment algorithm for Myelofibrosis:
   BMT Yes
   BMT No
   Bacigalupo A, Italy
   Barosi G, Italy
   Hill A, UK
3) How I treat PNH
4) Allogeneic HSCT for Aplastic anemia in first CR
5) Treatment of acute GVHD: Photoaheresis in first or second line?
6) HSCT in the outpatient setting: how can we manage it!
<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dino AMADORI</td>
<td>Oncologist at scientific Institute IRCCS - IRST, Meldola</td>
</tr>
<tr>
<td>Franco AVERSA</td>
<td>Professor at the University of medicine and surgery, Parma</td>
</tr>
<tr>
<td>Aleksandra BABIC</td>
<td>EBMT NG President, Mobilisation and Apheresis Unit IEO, Milano</td>
</tr>
<tr>
<td>Andrea BACIGALUPO</td>
<td>Professor at University of Cattolica del Sacro Cuore, Roma</td>
</tr>
<tr>
<td>Giovanni BAROSI</td>
<td>Epidemiologist at Policlinico S. Matteo, Pavia</td>
</tr>
<tr>
<td>Jacques Olivier BAY</td>
<td>Oncologist at Hospital Practitioner Head of Adult Clinical Haematology, Clermont Ferrand</td>
</tr>
<tr>
<td>Chiara BENNATI</td>
<td>Oncologist at Ospedale Santa Maria delle croci, Ravenna</td>
</tr>
<tr>
<td>Francesca BONIFAZI</td>
<td>Medical director at Policlinico S. Orsola - Malpighi, Bologna</td>
</tr>
<tr>
<td>Chiara BONINI</td>
<td>Hematologist at Ospedale S. Raffaele, Milano</td>
</tr>
<tr>
<td>Carmelo CARLOSTELLA</td>
<td>Professor of Hematology at IRCCS Istituto, Milan</td>
</tr>
<tr>
<td>Michele CAVO</td>
<td>Professor at University of Medicine, Bologna</td>
</tr>
<tr>
<td>Patrizia COMOLI</td>
<td>Medical doctor at Ospedale S. Matteo, Pavia</td>
</tr>
<tr>
<td>Antonio CUNEO</td>
<td>Head of Hematology unit at Arcispedale S. Anna university polyclinic, Ferrara</td>
</tr>
<tr>
<td>Paolomino Rafael DUARTE</td>
<td>Professor at University Hospital Puerta de hierro Majadahonda, Madrid</td>
</tr>
<tr>
<td>Carlo DUFOUR</td>
<td>Medical doctor of U. O. C. IRCCS Gaslini, Genova</td>
</tr>
<tr>
<td>Alois GRATWOHL</td>
<td>Professor Emeritus at the University, Basel</td>
</tr>
<tr>
<td>Anita HILL</td>
<td>Professor at St. James’s University Hospital, Leeds, UK</td>
</tr>
<tr>
<td>Francesco LANZA</td>
<td>Head section Hematology &amp; SCT unit Hospital, Ravenna</td>
</tr>
<tr>
<td>Alessandro LUCCHESI</td>
<td>Hematologist at scientific Institute IRCCS - IRST, Meldola</td>
</tr>
<tr>
<td>Mario LUPPI</td>
<td>Director of Chair and Division of Hematology University Unimore, AOO Policlinico, Modena</td>
</tr>
<tr>
<td>Fabio MALAVASI</td>
<td>Medical doctor at Ospedale Universitario Molinette, Torino</td>
</tr>
<tr>
<td>Giovanni MARTINELLI</td>
<td>Associate Professor Department of Experimental, Diagnostic and Specialty Medicine University, Bologna</td>
</tr>
<tr>
<td>Massimo Vincenzo MARTINO</td>
<td>Medical doctor at Ospedale Bianchi - Melacrino - Morelli, Reggio Calabria</td>
</tr>
<tr>
<td>Eoin MCGRATH</td>
<td>MBT Executive office, Barcelona</td>
</tr>
<tr>
<td>Arnon NAGLER</td>
<td>Medical doctor at Tel Hashomer (Sheba) Cord Blood Bank Hospital, RAMAT GAN, Israel</td>
</tr>
<tr>
<td>Andrea NECCHI</td>
<td>Medical doctor at Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</td>
</tr>
<tr>
<td>Attilio OLIVIERI</td>
<td>Head of HSC Transplant unit dept Hematology at o gist at Ospedali Riuniti, Ancona</td>
</tr>
<tr>
<td>Fabrizio PANI</td>
<td>Chairman Of SIE Società Italiana di Ematologia, Head Hematology unit at Università Federico II, Napoli</td>
</tr>
<tr>
<td>Paolo PEDRAZZOLI</td>
<td>Head of Oncology IRCCS Policlinico San Matteo, Pavia</td>
</tr>
<tr>
<td>Alessandro RAMBALDI</td>
<td>Head of Oncology and Hematology unit at AO Papa Giovanni XXIII, Bergamo</td>
</tr>
<tr>
<td>Patrizia TOSI</td>
<td>Medical director U. O. Hematology unit at Ospedale Infermi, Rimini</td>
</tr>
<tr>
<td>Sonja VLIEK</td>
<td>Resident Medical Oncology, PhD student NKI-AVL, Department of molecular pathology. Amsterdam</td>
</tr>
<tr>
<td>Francesco ZAJA</td>
<td>Professor at University of medicine, Udine</td>
</tr>
</tbody>
</table>
STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL DRUGS:
TOWARDS AN IMPLEMENTATION OF THE
TREATMENT PATHWAY IN ONCO-HEMATOLOGY

Ravenna Sala Corelli
Via Angelo Mariani 2

26 - 27 May 2017

ID ECM 2007 - 185655
Ecm Credits 6,3 (Formative credits used by Italian Ministry of Health)
the following professional categories may partecipate in the meeting
Surgeon
specialist in Hematology, Medical Genetics, Internal Medicine, Oncology, Radiotherapy, Pathological Anatomy,
Medical Genetics Lab, Trasfusion Medicine, General Medicine
Biologist
Biomedical Laboratory Technicians
Nurse

registration: www.proeventi.it

Event Organiser
www.proeventi.it